Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Jul 1;19(13):3331-3.
doi: 10.1158/1078-0432.CCR-13-1031. Epub 2013 May 28.

A neu view of invasive lobular breast cancer

Ron Bose  1
Affiliations
Comment

A neu view of invasive lobular breast cancer

Ron Bose. Clin Cancer Res. .

Abstract

Genome sequencing of relapsed, invasive lobular breast cancer identified actionable mutations in 86% of the cases. HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2-GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Molecular alterations in relapsed, lobular breast cancer. A, Development of lobular breast cancer from normal lobular epithelium of the breast. Loss of CDH1 (E-cadherin) and mutations or gene fusion of HER2 are likely driver events in this process. B, HER2 fusion gene combines exons 1-25 from HER2 with exons 12-15 from GRB7. The predicted fusion protein contains the HER2 extracellular domain (modeled with PDB accession: 1N8Y), HER2 tyrosine kinase model (PDB accession: 3PPO), and the GRB7 SH2 domain (PDB accession: 2QMS).
See this image and copyright information in PMC

Comment on

References

    1. Ross JS, Wang K, Sheehan CE, Boguniewicz A, Otto G, Downing SR, et al. Relapsed classic E-cadherin (CDH1) mutated invasive lobular breast cancer demonstrates a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res. 2013 - PubMed
    1. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149–56. - PMC - PubMed
    1. Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol. 2010;220:45–57. - PubMed
    1. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26:3006–14. - PubMed
    1. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461:809–13. - PubMed

Publication types